Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious ...

Among the three FDA-approved treatments, SPINRAZA and ZOLGENSMA are leading the market, with SPINRAZA securing a notable ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the company may look for a partner in obesity while focusing on rare diseases.

In October, Scholar Rock’s Phase 3 SAPPHIRE trial of apitegromab for SMA achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement for ...

Scholar Rock announces new preclinical SRK-439 data at ObesityWeek Largest borrow rate increases among liquid names Piper says trial suggests Lilly ‘liked what it saw,’ positive for Scholar Rock ...

We recently published 10 Big Names With Surprising Gains. Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of Wednesday’s best ...

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the ...

Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA).